Cancer Hospital, Chinese Academy of Medical Sciences

CancerFax acts as your single coordinator for the entire journey. You begin by sharing your medical records, including pathology reports, biopsy slides where available, recent imaging, molecular profiling and prior treatment summaries through our secure intake. Our clinical team reviews your case, identifies whether China's National Cancer Center is the right clinical and financial fit for your specific diagnosis (particularly strong for cancers prevalent in China such as esophageal, gastric, liver, lung and nasopharyngeal), and where useful compares it against other top cancer hospitals in China and internationally. We then submit your case to the hospital's International Medical Department, who arrange a fast-track consultation, multidisciplinary review or remote second opinion.

Once your consultation is confirmed, CancerFax prepares your full pre-travel pack: the hospital's official cost estimate (shared with you without any CancerFax mark-up), Chinese visa documentation, accredited translation of your home-country reports into Chinese, accommodation guidance in Chaoyang District near the main campus, and a clear plan for the typically longer evaluation timelines that come with high-volume public-hospital cancer care. We remain your single point of contact through admission, treatment and follow-up, and we will tell you honestly if a different cancer hospital would serve your specific case better. There is no fee to the patient for any of this coordination.

As China's National Cancer Center and the country's highest-volume public cancer institution, the hospital handles essentially every cancer type and sets national treatment guidelines. Its deepest internationally recognised expertise lies in cancers that are highly prevalent in China, where Chinese patients form the largest population worldwide: esophageal cancer (where its standardised treatment protocol won the first prize of the National Award for Scientific and Technological Progress), lung cancer, liver and hepatobiliary cancers, gastric cancer, nasopharyngeal carcinoma, colorectal cancer, breast cancer, and head and neck cancers. The hospital also has nationally leading surgical, radiation oncology and medical oncology departments for cancers including gynecologic, urologic, thyroid, melanoma and pediatric cancers. For patients from South Asia, Southeast Asia, the Middle East, Central Asia and Africa whose cancer profile often overlaps with Chinese patterns, this depth of disease-specific experience is genuinely difficult to match elsewhere.

Yes. The Cancer Hospital is the national pioneer in cancer clinical trials in China and a national drug clinical research base of the State Drug Administration, hosting the largest national portfolio of investigational cancer drug studies in the country. As one of the first national clinical medical research centres for malignant cancers, it offers access to phase 1 to phase 3 trials of investigational drugs that are frequently available years before international approval, often at significantly lower cost than equivalent trials in the United States or Western Europe. CAR T-cell therapy is available for selected hematologic malignancies, with Chinese-approved CAR-T products covered under China's National Reimbursement Drug List in many indications. For patients seeking specifically CD7 or other novel CAR-T constructs for haematologic relapse, CancerFax may also discuss Lu Daopei Hospital in Beijing alongside the Cancer Hospital pathway. CancerFax submits your records to the relevant clinical trials office to confirm whether a specific protocol matches your case.

Yes. The hospital's International Medical Department accepts foreign patients and arranges fast-track consultation scheduling, typically within three to ten days of records submission. For patients not yet able to travel, CancerFax facilitates a remote document-based second opinion through the International Medical Department, coordinates accredited Chinese-English translation of your reports, follows up on your behalf and helps you understand the resulting opinion, including how it compares with treatment plans from other top cancer centres. A remote opinion is often the most efficient first step for patients from South Asia, Southeast Asia, the Middle East, Central Asia and Africa who would otherwise need to travel before knowing whether China's National Cancer Center is the right clinical fit.

As a Chinese public hospital under the Chinese Academy of Medical Sciences, the Cancer Hospital offers cancer treatment at significantly lower cost than equivalent care at private international hospitals in China (such as Shanghai Jiahui International Hospital), in the United States, in Western Europe or in Singapore. For comparable major cancer surgeries, radiotherapy courses, chemotherapy cycles and immunotherapy regimens, costs are typically 40 to 80 per cent lower than US prices and often half the cost of high-end private hospitals in Asia. Some advanced therapies such as Chinese-approved CAR T-cell products are covered under China's National Reimbursement Drug List, materially reducing patient cost. The trade-off is that the patient experience is busier than at smaller private international hospitals, with English-language support more limited outside of the International Medical Department. CancerFax shares the hospital's official cost estimates with you at no extra charge and without any CancerFax mark-up, and we are happy to compare them openly with other cancer hospitals in China and internationally before any decision is made.